Asia Pacific Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)
The Asia Pacific pharmacogenomics market is expected to reach US$ 2,679.64 million by 2028 from US$ 1,148.36 million in 2021. It is estimated to grow at a CAGR of 11.2% from 2021 to 2028.
The key factors that are driving growth of the market are increasing demand for third generation sequencing along with growing funding for pharmacogenomic research activities. However, the dearth of skilled professionals is expected to restrict the market growth during the forecast period.
The development of newer and better DNA sequencing technologies has led to over a thousand-fold decrease in the cost of sequencing genomes since the launch of the Human Genome Project. The third generation of sequencing underwent development after the next-generation sequencing reached the market. Genomic sequencing technologies have revolutionized mutation detection of genetic diseases in the past few years. The third-generation sequencing (TGS) has gained insight into more genetic disorders due to the single molecular and real-time sequencing technology.
Pacific Biosciences developed new technologies called Single-Molecule Sequencing in Real-Time (SMRT). SMRT is quite efficient and uses fewer expensive chemicals. Its high sensitivity enables scientists to effectively observe DNA polymerase and watch it make a strand of DNA.
A rise in the demand for third-generation sequencing (TGS) technologies is attributed to the lucrative growth rate of the radiation dose management segment. With the emergence of TGS, genome sequencing has become a faster and more reliable method to study genomic variations. SMRT technology has allowed scientists to initiate re-sequencing of the sequenced genome to obtain higher accuracy. Escherichia coli is sequenced to an accuracy of 99.99% by using the SMRT technique.
Third-generation long-range DNA sequencing and mapping technologies are resulting in high-quality genome sequencing. Unlike second-generation sequencing, which produces short reads over a few hundred base pairs, third-generation single-molecule technologies generate over 10,000 bp reads or map over 100,000 bp molecules.
Pharmacogenomics is rapidly transitioning into clinical practice and implementation in healthcare systems supported by government investment totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives drive transformative change under real-life conditions while simultaneously addressing barriers against implementation and gathering evidence for broader adoption.
In April 2020, MedGenome—a Bengaluru-based genetic diagnostics, research, and data company—announced it had raised US$ 55 million (about INR 419 crore) in a new round of funding led by LeapFrog Investments, a global impact investment firm. Also, MedGenome claims to have built the largest database of South Asian genetic variants in genetic diagnostics in India and research partnerships. It has completed over 200,000 genomic tests to date and obtained samples from more than 550 hospitals and 6,000 clinicians across India. Thus, the continuous funding by manufacturers and governments in the genomics field is driving the pharmacogenomics market.
Asia Pacific Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
ASIA PACIFIC PHARMACOGENOMICS MARKET SEGMENTATION
By Technology
- Hospitals & Clinics
- Biopharmaceutical Companies
- CROs and CDMOs
- Others
By Application
- PCR
- Sequencing
- Microarray
- gel electrophorosis
- Mass spectrometry
- Others
By End User
- Drugs Discovery
- Oncology
- Neurological & Psychiatry
- Pain Management
- Cardiovascular
- Others
By Country
- Australia
- China
- India
- Japan
- South Korea
- Rest of APAC
Company Profiles
- Abbott
- F. HOFFMANN-LA ROCHE LTD.
- Oxford Nanopore Technologies
- THERMO FISHER SCIENTIFIC INC.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Pharmacogenomics Market – By Technology
1.3.2 Asia Pacific Pharmacogenomics Market – By Application
1.3.3 Asia Pacific Pharmacogenomics Market – By End User
1.3.4 Asia Pacific Pharmacogenomics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pharmacogenomics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. Pharmacogenomics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Growing Funding for Pharmacogenomics
5.2 Market Restraints
5.2.1 Lack of Skilled Professionals
5.3 Market Opportunities
5.3.1 Increasing Demand for Third Generation Sequencing
5.4 Future Trends
5.4.1 Increasing Demand for Personalized Medicines
6. Pharmacogenomics Market–Asia Pacific Analysis
6.1 Asia Pacific Pharmacogenomics Market Revenue Forecast and Analysis
7. Pharmacogenomics Market Revenue and Forecasts To 2028 – Technology
7.1 Overview
7.2 Asia Pacific Pharmacogenomics Market Share by Technology - 2021 & 2028 (%)
7.3 Polymerase Chain Reaction
7.3.1 Overview
7.3.2 Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.3 Real Time PCR
7.3.3.1 Overview
7.3.3.2 Real Time PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.4 Standard PCR
7.3.4.1 Overview
7.3.4.2 Standard PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.5 Digital PCR
7.3.5.1 Overview
7.3.5.2 Digital PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.4 Sequencing
7.4.1 Overview
7.4.2 Sequencing: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.5 Microarray
7.5.1 Overview
7.5.2 Microarray: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.6 Gel Electrophoresis
7.6.1 Overview
7.6.2 Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.7 Mass Spectrometry
7.7.1 Overview
7.7.2 Mass Spectrometry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8. Pharmacogenomics Market Revenue and Forecasts To 2028– by Application
8.1 Overview
8.2 Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
8.3 Drug Discovery
8.3.1 Overview
8.3.2 Drug Discovery: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.4 Oncology
8.4.1 Overview
8.4.2 Oncology: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.5 Neurology & Psychiatry
8.5.1 Overview
8.5.2 Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.6 Pain Management
8.6.1 Overview
8.6.2 Pain Management: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.7 Cardiovascular Disease
8.7.1 Overview
8.7.2 Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9. Pharmacogenomics Market Revenue and Forecasts To 2028 – End User
9.1 Overview
9.2 Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Biopharmaceutical Companies
9.4.1 Overview
9.4.2 Biopharmaceuticals Companies: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.5 CROs and CDMOs
9.5.1 Overview
9.5.2 CROs and CDMOs: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
10. Asia Pacific Pharmacogenomics Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Asia Pacific Pharmacogenomics Market Revenue and Forecasts To 2028
10.1.1 Overview
10.1.2 Asia Pacific Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.3 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.3.1 Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.4 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.5 Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%)
10.1.6.1 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.1.1 Overview
10.1.6.1.2 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.1.3 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.1.3.1 Japan: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.1.4 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.1.5 Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.2.1 Overview
10.1.6.2.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.2.3 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.2.3.1 China: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.2.4 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.2.5 China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6.3 India Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.3.1 Overview
10.1.6.3.2 India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.3.3 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.3.3.1 India: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.3.4 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.3.5 India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.4.1 Overview
10.1.6.4.2 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.4.3 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.4.3.1 South Korea: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.4.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.4.5 South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6.5 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.5.1 Overview
10.1.6.5.2 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
10.1.6.5.3 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.5.3.1 Australia: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.5.4 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.5.5 Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
10.1.6.6 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.6.1 Overview
10.1.6.6.2 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.6.3 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.6.6.3.1 Rest of Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.6.4 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.6.6.5 Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
11. Impact of COVID-19 Pandemic on Asia-Pacific Pharmacogenomics Market
11.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. HOFFMANN-LA ROCHE LTD.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Oxford Nanopore Technologies
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Illumina, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 QIAGEN
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Agilent Technologies, Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million).
Table 2. Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 3. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 4. Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 6. Japan: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 8. Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 9. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 10. China: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 11. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 12. China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 13. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 14. India: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 15. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 16. India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 17. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 18. South Korea: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 19. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 20. South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 22. Australia: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 23. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 24. Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 26. Rest of Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 28. Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 29. Organic Developments Done By Companies
Table 30. Inorganic Developments Done By Companies
Table 31. Glossary of Terms
LIST OF FIGURES
Figure 1. Pharmacogenomics Market Segmentation
Figure 2. Pharmacogenomics Market, By Country
Figure 3. Asia Pacific Pharmacogenomics Market Overview
Figure 4. PCR Segment Held Largest Share of Technology Segment in Pharmacogenomics Market
Figure 5. Asia Pacific Pharmacogenomics Market- Leading Country Markets (US$ Million)
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Asia Pacific Pharmacogenomics Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 9. Asia Pacific Pharmacogenomics Market Share by Segment - 2021 & 2028 (%)
Figure 10. Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 11. Real Time PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 12. Standard PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 13. Digital PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 14. Sequencing: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. Microarray: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Mass Spectrometry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
Figure 20. Drug Discovery: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Oncology: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Pain Management: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
Figure 27. Hospital and Clinics: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Biopharmaceutical Companies: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. CROs and CDMOs: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Asia Pacific Pharmacogenomics Market Overview, by Country (2021)
Figure 32. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%)
Figure 34. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
- Abbott
- F. HOFFMANN-LA ROCHE LTD.
- Oxford Nanopore Technologies
- THERMO FISHER SCIENTIFIC INC.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific pharmacogenomics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacogenomics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.